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REVIEW
Risk determination and prevention of breast
cancer
Anthony Howell1,2,3*, Annie S Anderson4, Robert B Clarke3, Stephen W Duffy5, D Gareth Evans1,2,6,
Montserat Garcia-Closas7, Andy J Gescher8, Timothy J Key9, John M Saxton10 and Michelle N Harvie1,2
Abstract
Breast cancer is an increasing public health problem. Substantial advances have been made in the treatment of
breast cancer, but the introduction of methods to predict women at elevated risk and prevent the disease has
been less successful. Here, we summarize recent data on newer approaches to risk prediction, available approaches
to prevention, how new approaches may be made, and the difficult problem of using what we already know to
prevent breast cancer in populations. During 2012, the Breast Cancer Campaign facilitated a series of workshops,
each covering a specialty area of breast cancer to identify gaps in our knowledge. The risk-and-prevention panel
involved in this exercise was asked to expand and update its report and review recent relevant peer-reviewed
literature. The enlarged position paper presented here highlights the key gaps in risk-and-prevention research that
were identified, together with recommendations for action. The panel estimated from the relevant literature that
potentially 50% of breast cancer could be prevented in the subgroup of women at high and moderate risk of breast
cancer by using current chemoprevention (tamoxifen, raloxifene, exemestane, and anastrozole) and that, in all
women, lifestyle measures, including weight control, exercise, and moderating alcohol intake, could reduce breast
cancer risk by about 30%. Risk may be estimated by standard models potentially with the addition of, for example,
mammographic density and appropriate single-nucleotide polymorphisms. This review expands on four areas:
(a) the prediction of breast cancer risk, (b) the evidence for the effectiveness of preventive therapy and lifestyle
approaches to prevention, (c) how understanding the biology of the breast may lead to new targets for prevention,
and (d) a summary of published guidelines for preventive approaches and measures required for their implementation.
We hope that efforts to fill these and other gaps will lead to considerable advances in our efforts to predict risk and
prevent breast cancer over the next 10 years.
Introduction
Breast cancer remains a major public health problem. The
incidence is rising in most countries and is projected to
rise further over the next 20 years despite current efforts
to prevent the disease [1-4]. The increased incidence is
not surprising since there has been, in most countries, an
increase in numbers of women with major breast cancer
risk factors, including lower age of menarche, late age of
first pregnancy, fewer pregnancies, shorter or no periods
of breastfeeding, and a later menopause. Other risk factors
which add to the burden of breast cancer are the increase
in obesity, alcohol consumption, inactivity, and hormone
replacement therapy (HRT) [4]. The impact of hereditary
breast cancer has also increased. For example, it is esti-
mated that the penetrance of the breast cancer 2 (BRCA2)
founder mutation in Iceland increased fourfold over the
last century, and the cumulative incidence of sporadic
breast cancer by age 70 also increased fourfold, from 2.5%
to 11% of the population, over the same period [5]. Birth
cohort effects have also been seen for both BRCA1 and
BRCA2 in other countries [6,7]. These data suggest that
both familial and non-familial risks have increased. The
Collaborative Group on Hormonal Factors in Breast Can-
cer (2002) estimated that the cumulative incidence of
breast cancer in developed countries would be reduced by
more than half, from 6.3 to 2.7 per 100 women, by age 70
if women had on average more children and breastfed for
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longer periods as seen in some developing countries [8].
Given global increases in population growth and the
strong evidence that a woman’s ability to control her fertil-
ity may improve her social, economic, and overall health,
it is not considered desirable to increase the birth rate per
woman or to encourage pregnancies at a very young age.
However, breastfeeding can and should be encouraged for
many reasons, including possibly for the reduction of
breast cancer risk. Many of the risks of reproductive fac-
tors are related to the effects of estrogen as demonstrated
by the reduction in breast cancer incidence after an early
oophorectomy, by inhibition of the estrogen receptor (ER)
by using selective estrogen receptor modulators (SERMs)
such as a tamoxifen or raloxifene [9], or by blocking estro-
gen synthesis by using aromatase inhibitors (AIs) such as
exemestane [10] and anastrozole [11,12].
A paradigm for preventative therapy (chemoprevention)
is cardiovascular disease (CVD). The introduction of drugs
that suppress cholesterol synthesis, modify platelet aggre-
gation, or lower blood pressure has led to a steady decline
in CVD over the past three decades, such that deaths from
CVD in women less than 85 years old fell below those for
cancer in 1999 [13]. The cardiovascular community is
helped by the reduction of a major risk factor (smoking)
and having easy-to-measure, repeatable biomarkers (chol-
esterol and blood pressure). CVD deaths are also reduced
by optimal treatment of disease once it arises; this is also
true for breast cancer treatment, in which (as a result of
the introduction of screening and optimizing treatments)
deaths have decreased by approximately one third over
the past 20 years. This is a major advance for breast can-
cer; however, primary prevention has not occurred at the
population level in contradistinction to CVD.
The fraction of breast cancer cases attributable to life-
style and environmental factors in the UK was estimated
to be 26.8% in 2010 [14], and a recent review suggests
that half of breast cancer cases may be prevented if
chemoprevention is applied in appropriate at-risk
populations and the major modifiable risk factors, in-
cluding achieving and maintaining a healthy weight,
regular physical activity (PA), and minimal alcohol
intake, are instituted [4]. Thus, there are further pos-
sibilities of important reductions in breast cancer inci-
dence. However, major gaps exist in our knowledge to
determine the risk of breast cancer accurately in order
to apply these approaches to appropriate populations of
women.
This review is an expansion and update of a brief review
published in the Gap Analysis in 2013 of breast cancer re-
search overall [1]. Besides summarizing new data pub-
lished over the past year, this review has enabled us to
give more comprehensive summaries of risk factors, ap-
proaches to prevention, and how understanding the biol-
ogy of the breast may lead to new approaches to risk and
prevention and also to expand on the all-important area
of how to implement current risk prediction and prevent-
ive measures in the population (Table 1).
Methods of risk assessment
Models and scoring systems have been developed either to
predict the probability that a person carries a mutation in
the BRCA1/2 genes, which is relevant to relatively small
numbers of women with strong family histories, or to pre-
dict breast cancer risk over time [15,16]. Computer models
such as BOADICEA (The Breast and Ovarian Analysis of
Disease Incidence and Carrier Estimation Algorithm) and
BRCAPRO (risk estimator for breast and ovarian cancer)
[17] and scoring systems perform well for predicting
BRCA1/2 mutation carrier probability, which is important
in deciding whether to perform a genetic test [18,19].
Of relevance to all women, several models have been
developed to predict risk of breast cancer over time (for
example, 5-year, 10-year, or lifetime risks). These predict
the probability that a woman in the population with a
particular combination of risk factors will develop breast
cancer [14-16]. The tested models include the Tyrer-
Cuzick [20] and Gail [21] models, both of which include
family history and non-familial risk factors, BOADICEA
[22], a modification of the Claus model to include non-
familial risk factors [23], the Rosner-Colditz model [24],
Table 1 Major gaps in our knowledge concerning risk
assessment and prevention of breast cancer
A. Gaps in risk estimation
A1. The best standard model to estimate risk in the general population
and in women at high risk
A2. What additional factors will give maximal improvement in a model?
A3. Prediction of risk in the proportion of women with none of the
current risk factors
B. Gaps in preventive therapy and lifestyle prevention
B1. Prediction of women who will benefit from current preventive therapy
B2. New agents for women who will not benefit from current
preventive therapy
B3. Optimal measures for weight control and exercise: timings of this in
the life course, who to target, and type of interventions
C. Gaps in understanding the biology of breast cancer risk
C1. Mechanisms of the effects of pregnancy on risk
C2. Mechanism of the lack of involution in some breasts with menopause?
C3. Mechanism of energy restriction on reduction of risk
D. Gaps in implementing known preventive measures
D1. Determination of the approximately 10% of women at high and
moderate risk in populations
D2. How to make preventive therapy available to the subset of women
who will benefit
D3. Optimal weight control and exercise programs for women at any
age and in all countries and how we engage individuals in cancer
prevention throughout the life course
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and several others, many of which require further valid-
ation [16].
The Gail model includes these risk factors: age at me-
narche, age at first live birth, number of previous breast
biopsies, benign breast disease, and number of first-
degree relatives with breast cancer. Studies indicate that
the Gail model is well calibrated in regularly screened
American women [25] and when using updated breast
cancer incidence [26]. However, recent studies in the UK
and US suggest that it may under-predict actual risk
relative to the Tyrer-Cuzick model [27-29], possibly be-
cause of the limited family history and not including age
of onset of cancer in the family whereas the Tyrer-Cuzick
model also includes second-degree family history, age of
onset of cancer, and use of HRT.
Although current models can give an accurate estima-
tion of lifetime risk (for example, we can tell a woman,
with some accuracy, that she has a 1 in 3 lifetime risk of
breast cancer), we cannot tell her whether she is the one
who will develop the disease or whether she is one of the
two women who will not. To fill this gap in our knowledge,
there is great interest in adding other risk factors to current
models, such as mammographic density [30,31], single-
nucleotide polymorphisms (SNPs) [32,33], estimation of
hormone levels [34], and lifestyle factors in order to test
whether they improve the accuracy of risk prediction in the
female population. Here, we examine recent progress made
in improving available breast cancer risk prediction models.
Improving risk estimation - mammographic density
The available data on mammographic density in relation
to breast cancer risk have been reviewed recently [30,31].
Dense tissue on the mammogram is white, whereas fat tis-
sue is radio-lucent and appears black. An overview of 42
studies of visually assessed mammographic density (the
proportion of the breast as a percentage which appears
white) indicated that the relative risk of breast cancer for
women with 70% or more density was 4.64-fold greater
compared with women with less than 5% density [35]. In
this report, the magnitude of the risk was greater using
percentage density than for other visual methods of density
estimation, such as Wolffe patterns or the Breast Imaging
Reporting and Data System (BI-RADS) classification,
which divides density into four visually assessed categories
and is widely used in the US. The distribution of visually
assessed mammographic density is shown in Figure 1.
Four studies have already assessed whether adding a meas-
ure of mammographic density improves risk estimation
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Figure 1 An example of the distribution of visually assessed percentage density of the breast. The sample consists of 50,831 women
between 46 and 73 years of age. Density was estimated in two views of each breast on a visual analogue scale, and the four readings were
combined to give a single value per woman [54].
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compared with the estimation using standard models
alone. A standard measure of improvement of risk assess-
ment is the C-statistic. This is the area under the receiver
operating curve (AUC), which in turn is a reflection of
the sensitivity and specificity of the model. The higher the
C-statistic (AUC), the greater the discriminatory accuracy
of the model. An AUC of 0.5 identifies a model whose dis-
criminatory accuracy is no better than chance alone,
whereas an AUC of 1.0 identifies a model with perfect dis-
criminatory accuracy. In practice, AUCs of 0.7 or 0.8 are
consistent with good discriminatory accuracy [15].
Tice and colleagues [36] estimated adding the BI-RADS
assessed density to the Gail model. The C-statistic for the
Gail model in this study was 0.67, but adding density to
the model modestly increased the C-statistic to 0.68, al-
though this small increase in discriminatory accuracy was
significant (P <0.01). Barlow and colleagues [37] reported
an increase of the C-statistic from 0.605 (95% confidence
interval (CI) 0.60 to 0.61) to 0.62 (95% C1 0.62 to 0.63)
also by adding BI-RADS density to the Gail model. Chen
and colleagues [38] demonstrated that adding percentage
density to the Gail Model 2 significantly (P = 0.015)
increased the C-statistic, from 0.602 to 0.664. Tice and
colleagues [39] performed a second study of adding
BI-RADS to a modification of the Gail model and re-
ported a C-statistic rise from 0.61 to 0.66. These studies
are important in that there was an improvement, albeit
modest, in discriminatory accuracy in all of them.
It should be borne in mind that owing to the correla-
tions among breast cancer risk factors, the addition of a
new risk factor, however powerful, to a model already con-
taining several risk factors will invariably make a modest
difference to prediction measures such as AUC. Whereas
some studies have suggested that density adds little to risk
prediction [40], some find AUCs for density or another
breast composition measure alone of 0.6 to 0.8 [41-44],
which is similar to those observed for the Gail and other
models.
Although the improvement in the C-statistic shown in
these studies is modest, a more relevant measure of the
utility of adding density information to risk models is how
much it improves the ability to identify women at different
levels of absolute risk for breast cancer (for example, re-
classification of women crossing threshold risk levels set
for public health interventions such as enhanced screening
or chemoprevention). Further validation of risk models, in-
cluding BI-RADS or other density measures such as volu-
metric approaches in prospective cohort studies, is needed
to assess potential value of density in risk-stratified pre-
vention or screening programs.
One method of density estimation, the interactive
thresholding technique known as CUMULUS developed
in Toronto [45], determines the area of dense and non-
dense tissue, unlike visual techniques outlined above,
and is widely regarded as a gold standard method for es-
timation of density. A meta-analysis of 13 case–control
studies using this technique indicated that the associ-
ation of density with risk was strong. Perhaps surpris-
ingly, the risk prediction was better for dense area as a
percentage of the whole breast rather than absolute
dense area [46]. There remains a need to assess whether
some measure of CUMULUS density adds to the pre-
dictive accuracy of standard models. CUMULUS is time-
consuming and requires specialized training, and the
technique will require greater automation to be useful
on a population basis (Nickson and colleagues [47]).
Methods are being developed to assess the volume of
dense and non-dense tissue in the breast and may be more
relevant not only because density is a volume but because
they can be partially or fully automated with the potential
for use in populations of women. The first reported esti-
mation of the relationship of volumetric density to stand-
ard risk factors was by Shepherd and colleagues [48], who
used a technique called single x-ray absorptiometry. In
their study, the C-statistic for risk factors alone was 0.609,
which significantly increased to 0.667 when log fibro-
glandular volume was added to standard risk factors. The
study was performed by using analogue mammograms.
Newer automatic techniques - such as Quantra (Hologic,
Inc., Bedford, MA, USA) and Volpara (Matakina Inter-
national, Wellington, New Zealand) - are designed for use
with modern digital mammograms and are fully auto-
matic. How they add to standard models is being tested,
but studies already demonstrate that they are consistent
with magnetic resonance imaging measures of volumetric
density [49,50].
Improving risk estimation - single-nucleotide
polymorphisms
Mutations in high-risk breast cancer genes such as
BRCA1/2 affect only small numbers of women, whereas
variation in lower-impact, common susceptibly loci or
SNPs can be responsible for a larger percentage of cancers
in the population. Although it has been predicted for
some time that risk would be related to polygenic inherit-
ance of common low-penetrance loci [51], these have only
recently been identified. SNPs are, by definition, common
alterations in the DNA code that are mostly thought to be
non-functional variants that frequently occur outside
functional genes. Relative risks from SNPs are small (max-
imum risk is around 1.43-fold) and many have effects of
less than 1.1-fold. Recent reports of ‘risk’ SNPs are a result
of large-scale multinational collaborations involving tens
of thousands of breast cancer cases and appropriate con-
trols. Such large-scale studies are required since each SNP
is associated with a small increase or decrease in risk.
However, in combination (for example, through polygenic
risk scores based on the average of the number of risk
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alleles weighted by the relative risk associated with each
allele), combined SNPs can be associated with substantial
increases or decreases in risk. The number of validated
SNPs associated with breast cancer risk is currently over
70, but it is thought that there may be hundreds more that
affect breast cancer risk [32].
Based on the first few SNPs identified, studies were
performed to determine how they might add to the Gail
model. All studies showed some improvement in the
C-statistic when SNP scores and the Gail model were
combined. Mealiffe and colleagues [52] using seven SNPs
reported an increase in AUC from 0.58 to 0.61 (P = 0.001),
Wacholder and colleagues [53] using 10 SNPs reported an
increase in the AUC from 0.58 to 0.62 (P <0.001), and Gail
[54] predicted an increase in the C-statistic from 0.61 to
0.63. More recently, Dite and colleagues [55] included
seven SNPs and reported an increase in AUC from 0.58 to
0.61 (P <0.001).
An additional way to determine the value of adding
SNPs to risk models is to assess changes in risk group
stratification before and after adding SNPs. For instance,
increasing the numbers of women estimated to be truly
at high or low risk would be of value clinically. All the
studies outlined above resulted in changes in classifica-
tion to higher and lower risk categories resulting in a
‘widening’ of the risk distribution curves. For example,
in the study by Comen and colleagues [56], a combin-
ation of 10 risk SNPs and the Gail model resulted in
20% of women being re-classified into a lower and 20%
into a higher risk group as defined by quintiles. More
recently, Brentnall and colleagues [57] and Evans and col-
leagues [58] estimated the effect on risk of combining 18
or 67 SNPs and the Tyrer-Cuzick model (Figure 2). Add-
ing more SNPs changed the risk distribution so that
more women were in the high- and low-risk groups, re-
spectively (Figure 2).
The studies outlined above highlight the prospects of
using SNPs for improved risk prediction in high-risk
clinics and in the general population. Further improve-
ments may come from introducing more SNPs and the
prospects of being able to predict the risk of specific
breast cancer subtypes, such as ER+ [59], ER− [60], grade
III [61], and triple-negative [62] tumors, separately, know-
ledge of which could direct preventative approaches [63].
Improving risk estimation - hormone measurements
Large studies with long-term follow-up indicate that many
hormones and growth factors are associated with an in-
creased risk of breast cancer. The important question is
whether any of them could be incorporated into models of
breast cancer risk prediction. The Endogenous Hormones
and Breast Cancer Collaborative Group reported that risk
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Figure 2 Estimation of the effect on the distribution of Tyrer-Cuzick scores by adding the results of 18 or 67 single-nucleotide
polymorphisms (SNPs) in 10,000 women [53]. Adding SNPs increases the number of women in high- and low-risk groups. ER, estrogen
receptor; SNP 18 and SNP 67, distribution using SNPs alone; TC, the Tyrer-Cuzick score alone; TC + SNP67, distribution of the combined score.
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of breast cancer was related to steroid hormones such as
estradiol, testosterone, and sex hormone-binding globulin
in pre- and post-menopausal women and was recently
confirmed in the European Prospective Investigation into
Cancer study [64-67]. The relation of body mass index
(BMI) with risk is attenuated by adjusting for estrogen,
but the relation of estrogen with risk is not attenuated by
adjusting for BMI. This is what would be expected if es-
trogen mediates the effect of BMI [64]. Thus, estrogens
may explain the increased risk of breast cancer in obese
post-menopausal women, although this does not preclude
other hormones and cytokines from mediating the effects
of estrogen (which may be more readily measurable) or
other mechanisms by which overweight and obesity might
affect risk [64,68].
The use of hormone measurements in breast cancer to
incorporate into risk models is attractive. However, meas-
urement, particularly in post-menopausal women, is prob-
lematic because of assay variation related to low hormone
levels and other unknown causes of variation in hormone
levels over time [69]. Nevertheless, Jones and colleagues
[70] demonstrated that change in estradiol and testos-
terone may be good biomarkers of the effectiveness of
weight loss and this is supported by recent data from
the Nurses’ Health Study [71]. Other growth factors/
hormones such as insulin-like growth factor-1 (IGF-1)
and prolactin are associated with breast cancer risk, par-
ticularly in post-menopausal women, and may possibly be
useful in models, although the risk increases between high
and lower risk groups of hormone concentrations are rela-
tively small [72-75].
Improving risk estimation - other methods
New biomarkers for risk prediction are likely to come
from measures in blood or tissues by a variety of tech-
niques. At present, it appears that none of these is ready
for incorporation into the standard models, but given
the pace of advance they are likely to be in the near fu-
ture. Examples of some current approaches include the
development of assays for serum antibodies against epi-
thelial antigens [76], gene expression in peripheral blood
white cells [77], blood epigenetic markers [78], and de-
velopments in high-throughput proteomics [79] and
adductomics [80]. Incorporating new risk markers into
risk models may not be straightforward since extensive
validation will be required and potential interactions
with known existing factors will need to be carefully
evaluated.
Breast cancer prevention
What can we advise women to do with respect to preven-
tion? Recent reviews focus on various aspects of preven-
tion, including SERMs and AIs for the chemoprevention
of ER+ cancers [81,82], chemoprevention for ER− cancers
[83,84], and lifestyle changes [4,85,86]. These reviews are
helpful in pointing out some areas that are potentially
clinically useful and others where far more investigational
work is required.
There is probably sufficient evidence from the ran-
domized trials for the use of SERMs and AIs for use in
women at high and moderate breast cancer risk [9,11]
and sufficient observational data to advise weight con-
trol, exercise, and moderation of alcohol intake [4,86]. In
this section, we review the data which support these
suppositions for each of the approaches to prevention;
in the next section, we review possible new investiga-
tional avenues.
Preventative therapy (chemoprevention)
There have been nine randomized trials of SERMs [9] and
two trials of AIs [10,11] mainly in women at increased risk
of breast cancer but also in women with osteoporosis or
heart disease (raloxifene). In the SERM trials, 83,399 par-
ticipants were included with 306,617 years of follow-up
over an average period of 65 months. The overall reduc-
tion in all breast cancer (including ductal carcinoma in
situ) using tamoxifen 20 mg per day was 38% (P <0.0001)
[9] with an estimated 10-year reduction in cumulative in-
cidence from 6.3% in the control group to 4.2% in the
SERM groups. This overview included the SERMs lasofox-
ifene and arzoxifene, which are not undergoing further de-
velopment by their respective drug companies. This leaves
tamoxifen and raloxifene as the two SERMs in clinical
practice. These were compared in a randomized trial
(the Study of Tamoxifen and Raloxifene, or STAR, trial)
[87]. Tamoxifen was significantly superior to raloxifene
in longer-term follow-up for preventing invasive breast
cancer (relative risk raloxifene/tamoxifen 1.24, 95% CI
1.05 to 1.47). Nonetheless, raloxifene was associated with
fewer side effects than tamoxifen, particularly with respect
to the uterus, and may be preferable in post-menopausal
women.
When given after surgery to prevent relapse of breast
cancer, AIs are generally superior to tamoxifen. This led
to the initiation of two placebo-controlled trials in post-
menopausal women at increased breast cancer risk. One
tested the AI exemestane and reported a reduction of
breast cancer risk of 65% after 5 years of treatment [10].
In the other trial (International Breast Cancer Interven-
tion Study II, or IBIS II), anastrozole was compared with
placebo [11]. In that study, 3,864 post-menopausal
women between 40 and 70 years of age at increased risk
of breast cancer were randomly assigned to anastrozole
1 mg per day or placebo for 5 years. A recent report in-
dicates that the incidence of breast cancer was reduced
by 53% (hazard ratio 0.47, 95% CI 0.32 to 0.68) by use of
anastrozole. Compared with SERMs, AIs are not associ-
ated with an increased risk of thromboembolic disease
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and uterine problems, including cancer, but are associ-
ated with increased mild to moderate bone/muscle pain
and reduced bone density.
Additional hormonal approaches to prevention sur-
round the use of HRT. Results from the Women’s Health
Initiative (WHI) randomized controlled trial of premarin
and medroxyprogesterone acetate indicate that the com-
bination given after menopause increases breast cancer
risk [88], a result supported by many observational stud-
ies. After the publication of the WHI study, many women
stopped HRT and it has been suggested by some to have
been associated with a reduction in the incidence of breast
cancer, CVD, and venous thrombosis as well as potential
considerable savings in health resources [89]. However,
the magnitude of these associations, as well as the ques-
tion of whether a cause-and-effect relationship exists, re-
mains controversial. In contrast, estrogen-only HRT using
premarin resulted in a reduction of the incidence and
deaths from breast cancer in the second WHI trial per-
formed in women with a previous hysterectomy [90]. This
result is supported by some, but not all, observational
studies and indicates that premarin may be regarded as a
breast cancer preventive agent [91].
Lifestyle
The World Cancer Research Fund/American Institute for
Cancer Research (WCRF/AICR) has estimated that over
40% of post-menopausal breast cancer could be prevented
by reductions in alcohol, excess body weight, and inactiv-
ity [92]. These estimates differ from those suggested by
others as outlined above [4,14], but all of the estimates
point in the same direction and indicate the import-
ance of lifestyle throughout the lifespan and the chal-
lenge of finding ways to support women to achieve
healthy ways of life.
Energy restriction/weight control
Strong observational data indicate that weight gain in the
premenopausal period and being overweight or obese after
menopause increase breast cancer risk [4,93]. In a meta-
analysis, Renehan and colleagues [93] estimated that for
each 5 kg/m2 increase in BMI the risk of breast cancer
was increased by 12%. Evidence from two large observa-
tional studies indicates that pre- or post-menopausal
weight loss reduces the risk of post-menopausal breast
cancer. In the Iowa Women’s Health Study, sustained
weight reduction of 5% of body weight reduced post-
menopausal breast cancer risk by 25% to 40% compared
with women who continued to gain weight [94]. In the
Nurses’ Health Study, post-menopausal women who did
not take HRT and maintained a body weight reduction of
10 kg or more had a 50% reduction in the risk of breast
cancer [95]. There is some evidence from the National
Surgical Adjuvant Breast Project P-I and STAR SERM
trials that weight reduction after the age of 35 is also ef-
fective [96]. It is important to emphasize the other well-
known beneficial effects of weight control, including the
reduction of diabetes [97,98] and CVD [99,100]. Modest
weight loss of 5% to 10% will reduce the risk of diabetes
by up to 60% and can reduce low-density lipoprotein chol-
esterol by 15% and triglycerides by 20% to 30%, increase
high-density lipoprotein cholesterol by 8% to 10%, and re-
duce blood pressure by around 5%. These changes in
CVD risk markers suggest a 30% or greater reduction in
risk of CVD.
Dietary components and prevention
There is great interest in determining whether components
of diets such as saturated fat content or the amount of fruit
and vegetables is related to the risk of breast cancer. A ran-
domized trial performed by the WHI of reduction of the
proportion of fat in the diet resulted in a non-significant
8% reduction in the risk of breast cancer, but there was
some confounding with weight loss [101]. After surgery for
breast cancer, where dietary interventions were performed
in addition to standard adjuvant therapy, reduction of fat
was associated with a 23% reduction in recurrence. This
study was also confounded by weight loss in the interven-
tion arm and thus in both studies the reason for the effects
on risks is not clear [102]. There was no advantage to an
increase of fruit and vegetable intake in another large ran-
domized adjuvant trial [103]. Recent large pooled analyses
have suggested that both dietary intake of vegetables and
circulating concentrations of some carotenoids may be in-
versely associated with the risk for ER− breast cancer but
not with the risk for ER+ disease. This topic requires fur-
ther investigation [104,105]. Whereas intervention studies
give little support for the preventive efficacy of specific
dietary components, prospective cohort studies provide in-
dications that adherence to dietary guidelines and certain
types of diet may impact on breast cancer risk. Adherence
to dietary and lifestyle guidelines appears to be beneficial.
In a study from Canada [106], adherence to the American
Cancer Society (ACS) and WCRF/AICR dietary/lifestyle
guidelines appeared to be beneficial: 49,613 women com-
pleted dietary and lifestyle questionnaires, and adherence
was associated with a 31% reduction of breast cancer esti-
mated over 16 years compared with women who did not
follow the guidelines. The guidelines include advice on
weight control, PA, alcohol intake, and intake of red meat,
vegetables, fruit, and sodium. In another study, the WHI
reported the effects of adherence to ACS guidelines in
65,838 post-menopausal women and indicated that adher-
ence to guidelines reduced breast cancer risk by 22% after
12.6 years of follow-up [107].
Adherence to dietary types may also affect risk. For ex-
ample, in the California Teachers Study, data from 91,779
women were analyzed according to predominant dietary
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pattern by using principal component factor analysis
[108]. A greater consumption of plant-based foods
was associated with a 15% reduction in breast cancer
risk (85% CI 0.76 to 0.95). A systematic review of dietary
patterns and breast cancer was performed by Albuquerque
and colleagues [109], who concluded that a Mediterranean
dietary pattern and diets composed largely of vegeta-
bles, fruit, fish, and soy are associated with a decreased
risk of breast cancer. Risk reduction may also be helped
by appropriate intakes of dietary fiber, fruit, and vege-
tables [110-114].
Physical activity
More than half of the US population does not meet the
recommended PA guidelines. In addition, the most re-
cent Health Survey for England [115] showed that over
40% of adult women (at least 19 years old) are not meet-
ing current guidelines of 150 minutes of moderate or
75 minutes of vigorous PA per week [116]. The WCRF/
AICR Expert Report [117] described the evidence for an
inverse association between PA and breast cancer risk as
‘probable’ and ‘limited - suggestive’ for post- and pre-
menopausal women, respectively. A more recent review
of 73 observational studies indicated that moderate to
vigorous PA reduces breast cancer risk by an average of
25% in pre- and post-menopausal women compared with
inactive women [118]. The strongest inverse associations
with breast cancer risk were observed for recreational PA,
lifetime PA, post-menopausal PA, and participation in
moderate to vigorous PA. There was also evidence of
dose–response relationships, with higher volumes of PA
associated with greater risk reduction, but with the most
pronounced reductions in risk being observed in lean ver-
sus obese women. The optimal level of PA for breast can-
cer risk reduction is unclear, however, and may be greater
than current recommendations [118]. A major limitation
of observational studies is the heterogeneity of self-report
questionnaires that have been used to measure PA. The
use of more objective measures, such as 7-day accelerome-
try, would provide more robust PA data. There is a clear
need for randomized controlled trials which include clin-
ical end-points or biomarkers on the causal pathway, but
designing such trials is challenging because of the large
sample size required and the expense of collecting long-
term follow-up data.
Alcohol
It is estimated that breast cancer risk is increased by 7%
to 10% for each one-unit increase in intake of alcohol
per day (a unit is half a pint of 4% strength beer or cider
or 25 mL of 40% strength spirits, and a small 125-mL
glass of 12% strength wine is 1.5 units). In the Nurses’
Health Study, women who consumed 4 to 9 units per
week were 15% more likely to develop breast cancer
compared with never drinkers [119]. Women with the
highest alcohol intake (of at least 27 units per week)
were 51% more likely to develop breast cancer compared
with non-drinkers. These studies suggest that women
who want to minimize their breast cancer risk should not
be drinking more than one unit daily and probably have at
least two alcohol-free days weekly. Studies show that the
negative effect of alcohol may be abrogated by adequate
dietary folate intake (rather than supplements) and should
be pointed out as a preventive measure for women who
find reduction in alcohol intake difficult [120]. Better life
expectancy associated with moderate alcohol intake com-
pared with none in a large meta-analysis should be bal-
anced against recommending zero intake [121].
It is important to be aware that lifestyle prevention in-
cludes not only middle- and late-age women but youn-
ger women after menarche. Animal experiments and
modeling of the reproductive events in women indicate
that the most susceptible period for carcinogenesis is
during the period between menarche and first pregnancy
[122,123]. In women, this susceptibility is highlighted by
the increase in premalignant lesions in the breast of
women who drank alcohol or smoked (or both) during
this period of early life [124].
The biology of risk and prevention as an indicator
of potential new approaches
One way to develop new approaches to prevention is to
assume that understanding the biological basis of breast
development will give indications of potential targets
for therapeutic interventions. Great insights into the
mechanisms of breast development in utero and at pu-
berty, particularly in the rodent mammary gland, have
been discovered and are summarized in recent reviews
[125,126]. They highlight the crucial importance of
epithelial-stromal interactions for normal breast develop-
ment and of the individual cell types within the stroma,
including immune cells, fibroblasts, or adipocytes. Import-
antly, it has been shown that experimental inhibition of
any one of these interactions results in lack of breast de-
velopment and this has implications for our thinking
about approaches to prevention (Figure 3).
The experiments outlined above cannot be performed in
humans. However, another approach to the development of
prevention is understanding the biological mechanisms of
risk factors for breast cancer. Here, we discuss some exam-
ples which support this view with respect to estrogen and
the breast, early and late first pregnancy, menopausal invo-
lution of epithelial cells, mammographic density, and mech-
anism of the effects of energy restriction and exercise.
Estrogen and the breast
The most successful preventative approach to breast can-
cer to date, reducing the effects of estrogen on the breast,
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has come from an understanding of the biology of the ER
and the knowledge that estrogen is synthesized in the
breast and elsewhere after ovarian function decreases at
menopause. These data have led to the introduction of the
SERMs (tamoxifen and raloxifene) and the potential intro-
duction of AIs (exemestane and anastrozole) for breast
cancer prevention. Tamoxifen acts by blocking the ER but
under certain circumstances can change to being a partial
agonist via the ER and this may limit its preventive utility
since in some women at increased risk it appears to in-
crease mammographic density [127]. The development of
orally active ER downregulators similar to fulvestrant
(which has to be given intramuscularly, thus limiting its
preventive utility) may be superior to tamoxifen (for ex-
ample, ARN-810, NCTO1823835) [128]. Another poten-
tial way to enhance the therapeutic ratio of tamoxifen is to
use low doses or to combine tamoxifen with retinoids
such as fenretinide; studies of these approaches are under
way in prevention trials in Italy [129]. Another approach
may be a combination with low-dose aspirin, which has
some minor preventive effects on breast cancer risk but
would help combat the increased risks of thromboembolic
disease with tamoxifen.
Mimicking the protective effects of an early first
pregnancy
Recent insights into the effects of early first pregnancy
of the normal breast in young women give clues to how
we might mimic this effect therapeutically. Since the dem-
onstration that ER+ and progesterone receptor-positive
(PR+) cells in the normal breast rarely proliferate [130], it
has been shown, for example, that progesterone binds to
its receptor on the PR of the epithelial cell and stimulates
the synthesis and release of paracrine mediators such as
Rank (receptor activator of nuclear factor-kappa-B), Wnt
(wingless related integration site), and growth hormone,
which in turn stimulate adjacent stem and progenitor cell
expansion [131,132]. Recently, it was shown that early
first pregnancy in women reduces the number of PR+
cells and downregulation of paracrine mediators, result-
ing in a reduction of the stem/progenitor cell compart-
ment [133]. These data suggest that modulating the effect
S
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Figure 3 Features of the normal breast. (a) Electron micrograph of a ductule of the breast. (b) Section of lobules of the breast showing
a relationship with collagenous and fatty stroma. Reprinted with permission from the American Association for Cancer Research [166].
(c) A simplified cartoon of reported potential interactions between three cell types in the stroma and the epithelium of the breast. CSF,
colony-stimulating factor; ER, estrogen receptor; IGF1, insulin-like growth factor 1; PR, progesterone receptor; PTH, parathyroid hormone;
TDLU, terminal duct lobular unit.
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of progesterone by the use of antiprogestins should be ex-
plored for breast cancer prevention [134].
Establishing the cause of the inverse association between
childhood/adolescent obesity and lower risk of breast
cancer
Observational data have linked diet and growth in height
in childhood and dietary exposures during early adult-
hood (that is, between menarche and first full-term
pregnancy to later risk of breast cancer). These studies
have either used retrospective recall of early life expo-
sures from adults or prospectively assessed short-term
effects on surrogate risk markers like benign breast dis-
ease [135]. Studying lifestyle exposures in this period is a
challenge which has understandably received less re-
search attention than exposures later in life. The period
between menarche and first full-term pregnancy is a pri-
ority for research since risk can accumulate rapidly in
this period until terminal differentiation that accompan-
ies first pregnancy.
Key observations which deserve further study are the re-
duced breast cancer risk with a higher BMI in early adult-
hood (that is, at the age of 18 to 21), reported from
numerous prospective studies among Caucasian [136,137],
black [138], and Asian [139] populations. This observation
is partly explained by smaller adult weight gains, which
are consistently reported among heavier young women
[140-143]. Other possible mechanisms which may put
heavier women at lower risk than their lean counterparts
include higher estrogen levels, which may upregulate the
BRCA1 tumor-suppressor gene, earlier differentiation of
breast tissue [9], subsequent lower IGF-1 levels in adult-
hood [144], and a slower pubertal growth and sexual mat-
uration despite their early menarche [135]. Increased
irregular cycles are often cited as a likely protective mech-
anism but are not supported by available data [145]. Like-
wise, height velocity has been linked to risk of breast
cancer [146] and benign breast disease [147], which in
turn may be linked to dietary patterns which are high in
animal versus vegetable protein and lower in fiber and iso-
flavones [148].
Reversing the promotional effects of late pregnancy
Late pregnancy is a major driver of the worldwide in-
crease in breast cancer incidence. Over half of women in
the UK have their first pregnancy over the age of 30, and
thus understanding the mechanism of its effect on risk
is of great importance. It seems likely that the breasts of
older fertile women harbor early pre-cancerous lesions.
One mechanism in which these may be stimulated is as
a result of immunological processes that occur during
post-partum breast involution. Lyons and colleagues
[149] demonstrated an increase in cyclooxygenase 2 dur-
ing involutional macrophage infiltration and showed that
ibuprofen reduces post-partum breast cancer in these
models. Ibuprofen might be tested in women at high risk
because of late pregnancy and a positive family history
[148,149]. Premalignant lesions in the breast have indeed
been detected by review of serial sections of the breasts at
post-mortem of older premenopausal women and found
to be present in up to one third of women [150,151].
It is clear that most do not progress to breast cancer
since the incidence of the disease is not that high. Re-
cently, Haricharan and colleagues [152] demonstrated that
the signal transduction molecule pSTAT5 (phospho-signal
transducer and activator of transcription 5) is activated by
inhibiting apoptosis in premalignant lesions that progress
to forming cancer. Inhibitors of this pathway are in the
clinic and ultimately could be used for prevention [153].
Failure of menopausal breast involution
The lobules of the breast undergo involution after meno-
pause. However, Wellings and colleagues [154] reported
atypical premalignant lobules which persisted after meno-
pause where menopausal regression might be expected. In-
vestigators at the Mayo Clinic noted, by careful histological
examination of biopsies of the breast of post-menopausal
women, that the breast lobules in some women did
not undergo post-menopausal involution and that these
women were at high risk of subsequent breast cancer
[155]. As a measure of the importance of this observation,
the authors investigated how the lack of involution com-
pared with risk prediction of the Gail model in this group
of women. The C-statistic for the Gail model of the pa-
tients studied was 0.60. For lobular involution (or not),
the C-statistic was 0.66. Combining Gail risk and involu-
tion did not change the latter figure [156]. There are, as
far as we are aware, no published data on the mechanism
of lack of post-menopausal involution but this may be
similar to the lack of involution after a pregnancy [152].
The reduction of apoptosis reported in animal models of
pregnancy involution was reported in women [157]. In the
clinic, there are agents to enhance apoptosis, such as
ABT-263, with potential for transfer to prevention if tox-
icity could be reduced [158].
Mechanism of mammographic density
Some studies show that the rate of the well-known de-
cline of mammographic density with age is slower in
some women and indicates higher breast cancer risk
[159,160]. Methods to reduce density may prevent breast
cancer. As proof of principle of this hypothesis, Cuzick
and colleagues [127] demonstrated in the IBIS-I preven-
tion trial that women who had a more than 10% reduc-
tion in density with tamoxifen had a 70% reduction in
risk of breast cancer risk but that for women with less
or no reduction in density there was no reduction in
risk. Investigation of the reasons for the lack of effect of
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age and of tamoxifen on some breasts is clearly import-
ant [161].
Gene expression profiles of fibroblasts derived from
dense and non-dense areas of the breast indicate marked
differences in expression. Expression of genes associated
with inflammation (such as c-Jun N-terminal kinases, or
JNK) and several signaling pathways is upregulated and
suggests the use of, for example, JNK inhibitors, already in
the clinic for treatment of overt disease [162,163]. Some
fibroblasts in dense areas resemble cancer-associated fi-
broblasts in their signaling pathways and production of
extracellular aligned collagen, all potential targets for pre-
vention [164].
Energy restriction mimetics
Energy restriction is well known to increase longevity in
several types of organisms, in part by reducing the inci-
dence of cancer. It acts predominantly by reversing the
effects of obesity on inflammation, certain signal trans-
duction pathways, and insulin/IGF-1 [165]. Obesity is as-
sociated with macrophage infiltration and activation in fat,
which in turn results in cytokine production and increased
aromatase activity and estrogen production [166,167].
Obesity also results in reduced insulin sensitivity and al-
tered signal transduction pathways, such as P13Kinase
and mammalian target of rapamycin (mTOR), and in
mitochondrial metabolism [168,169]. Some agents which
beneficially reduce activity of these pathways such as
mTOR inhibitors are already in the clinic, and others such
as metformin and SIRT 1 activators such as resveratol
and other activators of sirtuins are under investigation
[170]. Doubt has been cast on the value of metformin
[171], giving added importance to the randomized trial
of adjuvant metformin instigated by Goodwin and col-
leagues [172].
Physical activity
Several biological mechanisms have been proposed to ex-
plain the inverse association between PA and breast can-
cer risk. Although regular exercise may delay the onset of
menarche, increase the length of the menstrual cycle, or
increase the number of anovulatory cycles, hence reducing
exposure to sex hormones, prospective intervention stud-
ies suggest that high levels of exercise may be needed to
induce menstrual cycle changes [173,174]. Other possible
mechanisms include improvements in insulin sensitivity,
immune function/surveillance, and antioxidant defense
capacity as well as alterations in gene function or apop-
tosis [175,176]. Studies have also highlighted a potential
role for epigenetic mechanisms which could reduce breast
cancer risk in physically active women, including an
increase in LINE-1 (long interspersed nucleotide elements-1)
methylation (index of global DNA methylation) and an
increase in the methylation of tumor-suppressor genes
[176,177]. Moderate levels of PA may also increase the
expression of telomere-stabilizing proteins, thereby at-
tenuating the effects of aging on telomere length and po-
tentially reducing the risk of age-related diseases such as
breast cancer [178,179].
PA could also influence breast cancer risk through its
effect on weight loss and reduced levels of body fat. This
means that distinguishing the independent effects of PA
on breast cancer risk is difficult because body fat reduc-
tion impacts a range of putative breast cancer risk
markers, including circulating levels of sex hormones,
insulin-like growth factors, adipokines, and inflammatory
mediators [173]. Elevated circulating levels of adipokines
such as leptin, interleukin-6, and tumor necrosis factor-
alpha and the acute phase protein C-reactive protein as
well as reduced levels of adiponectin are associated with
high levels of body fat [173,180], whereas weight loss in-
terventions involving PA evoke reductions in circulating
levels of inflammatory markers and leptin while in-
creasing circulating levels of adiponectin [181,182]. Des-
pite this, evidence from both human [173,174] and animal
[175,183] studies suggests that regular aerobic exercise
can induce changes in biological risk factors (for example,
sex hormones, insulin sensitivity, antioxidant defense cap-
acity, and intracellular signaling pathways) that are inde-
pendent of PA-induced changes in body weight and body
composition.
The studies outlined above indicate the interactions
which occur between epithelial cells and between them
and stromal cells such as macrophages, fibroblasts, and
adipocytes (Figure 3). They indicate the potential for new
approaches to prevention, although translation to the
clinic will be difficult. An excellent discussion of the prob-
lems is given by Strasser-Weippl and Goss [184].
Clinical application
Guidelines
Preventive therapy
Several guidelines advise how we might apply the know-
ledge that we have gained concerning hormonal preven-
tion (tamoxifen, raloxifene, exemestane, and anastrozole)
and lifestyle factors (weight control, exercise, and limita-
tion of alcohol) to populations of women. Hormonal che-
moprevention is suggested for women at increased risk,
whereas lifestyle factors can be applied to all women since
all are at some risk of breast cancer, and even at low risk,
lifestyle factors are similar to those which help prevent
other conditions such as CVDs and diabetes.
Three major sets of clinical guidelines were published
concerning the selection of women for chemoprevention
in 2013. The US Preventive Service Task Force gives
guidelines for prescription of medication for risk reduc-
tion of breast cancer [185]. The recommendation applies
to asymptomatic women 35 years or older without a prior
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diagnosis of breast cancer, ductal carcinoma in situ, or
lobular carcinoma in situ. They advise use of the Gail
model to assess risks and a cutoff of 1.66% 5-year risk.
However, taking toxicity into account, they suggest that a
threshold for advising treatment of 3% 5-year risk may be
more appropriate and advise use of the tables pub-
lished by Freedman and colleagues [186] and, as in the ta-
bles, that the balance for use/no use depends on age, race/
ethnicity, the medication used, and whether the woman
has a uterus.
The American Society of Clinical Oncology published
their clinical practice guideline in August 2013 [187].
The report included a systematic review of randomized
controlled trials and meta-analyses published between
2007 and 2013 which identified 19 trials and six chemo-
prevention agents. In women who are at increased risk
of breast cancer and who are more than 35 years old,
they suggest that tamoxifen (20 mg per day for 5 years) be
discussed as an option to reduce the risk of ER+ breast
cancer. In post-menopausal women, raloxifene (60 mg per
day for 5 years) and exemestane (25 mg per day for
5 years) should also be discussed as options for breast can-
cer risk reduction. Those at increased breast cancer risk
are defined as individuals with a 5-year projected absolute
risk of breast cancer of more than 1.66% (based on the
National Cancer Institute Breast Cancer Risk Assessment
Tool or an equivalent measure) or women diagnosed with
lobular carcinoma in situ. SERMs are not recommended
for use in women with a history of deep vein thrombosis,
pulmonary embolus, stroke, or transient ischemic attack
or during prolonged immobilization or in combination
with HRT. In this update of the guideline published in
2009, the phrase ‘may be offered’ was replaced by ‘should
be discussed as an option’ in women at increased risk of
breast cancer [187]. The American Society of Clinical
Oncology reviewers concluded that ‘research is needed to
address the many unresolved issues related to the poor
uptake of breast cancer chemoprevention agents in
women who are at increased risk. These include (1) the
design of effective tools and approaches to educate pro-
viders on the option of chemoprevention, (2) efficacious
interventions that communicate to eligible women the
risks and benefits of specific chemoprevention agents,
(3) the development of tools that more accurately
identify women at increased risk, and (4) a greater under-
standing of what disparities and barriers exist with regard
to chemoprevention use among women at higher risk for
breast cancer’ [187]. The document provides in-depth re-
views of all of the important trials.
The UK National Institute of Health and Care Excel-
lence published guidelines for women at increased risk
of breast cancer by virtue of a family history of the dis-
ease [188]. For the first time in the UK, their recommen-
dation was that women at greater than 30% (1 in 3-4+)
lifetime risk of breast cancer be ‘offered’ tamoxifen or
raloxifene and that in those at greater than 17% (1 in 6+)
lifetime risk preventive therapy be ‘considered’ for treat-
ment. They did not endorse use of AIs, since the IBIS-2
study had not been published at the time, but did suggest
that a lifestyle advice leaflet be given.
Lifestyle change
The ACS published guidelines on nutrition and PA mea-
sures for cancer prevention in 2012 [189]. The guidelines
were based on published data. Randomized controlled tri-
als were given greatest credence and cohort studies over
case–control studies. Four lifestyle choices were recom-
mended to reduce cancer risk: (a) achieve and maintain a
healthy weight throughout life, (b) adopt a physically ac-
tive lifestyle, (c) consume a healthy diet, with an emphasis
on plant foods, and (d) limit consumption of alcoholic
beverages.
Importantly, recommendations were also made for
introduction of the guidelines into the community: ‘Pub-
lic, private, and community organizations should work
collaboratively at national, state, and local levels to im-
plement policy and environmental changes…’ [190].
The Second WCRF/AICR Expert Report (Food, Nutrition,
Physical Activity, and the Prevention of Cancer: A Global
Perspective) was published in 2007 [117] and is continu-
ally updated [190]. The recommendations are similar to
the ACS guidelines and are relevant to the prevention of
other conditions such as CVD.
Implementation
The guidelines outlined above are based on the best avail-
able knowledge and seem eminently sensible. It is widely
appreciated that their implementation is a major and long-
term problem. Although several models give reasonable
indicators of risk of breast cancer, detecting women
at risk in the population is problematic. For example,
women with only a minor family history but with endocrine
risk factors are very often not aware of their breast cancer
risks. One solution is to use mammographic screening
programs as a time to communicate risk information (in-
cluding lifestyle parameters) and to highlight/signpost
access to preventive therapy lifestyle programs [58,191].
In a program in Manchester, UK, collecting risk informa-
tion at screening was shown to be feasible, and 95%
of women indicated that they wished to know their
risks of breast cancer [58]. Women at high risk can be
offered preventive therapy in the context of specialist
clinics, but on a population basis it may be optimal to im-
plement risk assessment and treatment in general practi-
tioner practices as is the case for the prevention of CVD
in clinical practice.
For lifestyle change, the goals for breast cancer preven-
tion are the same as those required to solve the obesity
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epidemic. These are very well highlighted in the goals set
by the US Institute of Medicine report on ‘Accelerating
Progress in Obesity Prevention: Solving the Weight of the
Nation’ [192]. The goals of the program encompassed
integrating PA as a routine into everyday life, making
healthy foods and beverages available everywhere, market-
ing messages pertaining to healthy nutrition and PA and
expansion of the role of health-care providers, insurers,
employers, and schools as national focal points for obesity
prevention. The national (US) progress of this very broad
and crucial program was summarized in a recent work-
shop [193]. The US Institute of Medicine believes that the
obesity problem will be solved only by mobilizing the
population of all ages for there to be an accelerated trans-
formation to the obesity problem (Figure 4). The docu-
ments suggest groundbreaking approaches; similar ones
could be adapted to other developed and developing
countries.
Colditz and colleagues [194] recently summarized the
critical barriers to change for the prevention of cancer in
general. These included (a) skepticism that cancer can
be prevented, (b) the short-term focus of cancer re-
search, (c) interventions deployed too late in life, (d) re-
search focus on treatment not prevention, (e) debates
among scientists, (f ) societal factors which affect health
outcomes, (g) lack of transdiciplinary approaches, and
(h) the complexity of successful implementation. These
are barriers to be overcome.
Conclusions
One conclusion of this review is that the application
of measures that are already available, such as chemopre-
vention and lifestyle prevention, would result in ap-
preciable reductions in breast cancer risk. A second
conclusion is that the pace of advance of our understand-
ing of the biology of breast cancer risk and development
is highly likely to give rise to new avenues for preven-
tion over the next 10 years. A major problem is applying
what we already know concerning the efficacy of preven-
tion to appropriate populations of women. To apply che-
moprevention, we need to have measures in place to
assess risk and to explain the pros and cons of treatment
and for prescription of appropriate therapies. Lifestyle
change is a population problem which involves publicity
concerning its risks and benefits of change and providing
mechanisms to support women in their choices through-
out society as highlighted in the US Institute of Medicine
documents.
Physical
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Figure 4 US Institute of Medicine blueprint for lifestyle change. Reprinted with permission from the US Institute of Medicine [192].
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